CO6470863A2 - Mutantes fgf21 y usos de los mismos - Google Patents

Mutantes fgf21 y usos de los mismos

Info

Publication number
CO6470863A2
CO6470863A2 CO11167163A CO11167163A CO6470863A2 CO 6470863 A2 CO6470863 A2 CO 6470863A2 CO 11167163 A CO11167163 A CO 11167163A CO 11167163 A CO11167163 A CO 11167163A CO 6470863 A2 CO6470863 A2 CO 6470863A2
Authority
CO
Colombia
Prior art keywords
polypeptides
amino acid
substitution
methods
mutant
Prior art date
Application number
CO11167163A
Other languages
English (en)
Inventor
Edward John Belouski
Murielle Marie Ellison
Randy Ira Hecht
Yue-Sheng Li
Mark Leo Michaels
Jeonghoon Sun
Jing Xu
Agnes Eva Hamburger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42455356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6470863(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO6470863A2 publication Critical patent/CO6470863A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Proteína FGF21 humana que tiene propiedades mejoradas tal como una vida media incrementada y/o agregación disminuida se puede preparar usando los métodos dados a conocer en este documento y métodos de biología molecular estándares características de la Invención: Polipéptido aislados que comprenden una secuencia de aminoácidos de SEQ ID NO: 4 y que comprende además: (a) al menos una sustitución de aminoácidos en la posición 180; y (b) al menos una sustitución de aminoácidos seleccionada del grupo que consiste de: (i) una sustitución en la posición 171; y (u) una sustitución en la posición 98; y (c) combinaciones de los mismos.Campo de Aplicación: Moléculas de ácido nucleico que codifican Polipéptido mutantes FGF2 1, polipéptidos mutantes FOF2 1, composiciones farmacéuticas que comprenden polipéptidos mutantes FGF21 y métodos para tratar trastornos metabólicos usando estos ácidos nucleicos, polipéptidos o composiciones farmacéuticas."
CO11167163A 2009-05-05 2011-12-05 Mutantes fgf21 y usos de los mismos CO6470863A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17573609P 2009-05-05 2009-05-05
US28511809P 2009-12-09 2009-12-09

Publications (1)

Publication Number Publication Date
CO6470863A2 true CO6470863A2 (es) 2012-06-29

Family

ID=42455356

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11167163A CO6470863A2 (es) 2009-05-05 2011-12-05 Mutantes fgf21 y usos de los mismos

Country Status (37)

Country Link
US (4) US8188040B2 (es)
EP (3) EP3248610B1 (es)
JP (1) JP5823954B2 (es)
KR (2) KR20180014235A (es)
CN (2) CN102655877B (es)
AR (1) AR076541A1 (es)
AU (1) AU2010246108B2 (es)
BR (1) BRPI1011404B1 (es)
CA (1) CA2760196C (es)
CL (1) CL2011002768A1 (es)
CO (1) CO6470863A2 (es)
CR (1) CR20110639A (es)
DK (1) DK3248610T3 (es)
EA (1) EA021425B1 (es)
ES (2) ES2632742T3 (es)
FI (1) FI3248610T3 (es)
HK (1) HK1247134A1 (es)
HR (1) HRP20240135T1 (es)
HU (1) HUE065036T2 (es)
IL (2) IL215937A (es)
JO (1) JO3469B1 (es)
LT (1) LT3248610T (es)
MA (1) MA33716B1 (es)
MX (1) MX2011011709A (es)
MY (1) MY156542A (es)
NZ (1) NZ596037A (es)
PE (2) PE20120358A1 (es)
PH (1) PH12015502433A1 (es)
PL (1) PL3248610T3 (es)
PT (1) PT3248610T (es)
RS (1) RS65153B1 (es)
SG (3) SG175861A1 (es)
SI (1) SI3248610T1 (es)
TW (2) TWI436776B (es)
UY (2) UY38740A (es)
WO (1) WO2010129503A1 (es)
ZA (1) ZA201108371B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
DK3248610T3 (da) 2009-05-05 2024-01-15 Amgen Inc Fgf21-mutanter og anvendelser deraf
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
EP2707718A1 (en) * 2011-05-10 2014-03-19 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
AU2012301769B2 (en) * 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
AU2015202304C1 (en) * 2011-09-26 2017-03-09 Novartis Ag Fusion proteins for treating metabolic disorders
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
CN103923207B (zh) * 2014-04-08 2016-03-09 东北农业大学 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3209681A4 (en) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
PT3236991T (pt) 2014-12-23 2019-09-06 Novo Nordisk As Derivados de fgf21 e usos dos mesmos
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US20180071981A1 (en) 2015-03-31 2018-03-15 The Regents Of The University Of California System and method for tunable patterning and assembly of particles via acoustophoresis
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN108350072B (zh) * 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
EP3355908A1 (en) * 2015-10-01 2018-08-08 Amgen Inc. Treatment of bile acid disorders
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
AU2017317183A1 (en) * 2016-08-22 2019-02-07 Ambrx, Inc. Bovine fibroblast growth factor 21 and ketosis in dairy cattle
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3042512A1 (en) 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
RU2019122785A (ru) 2016-12-22 2021-01-22 Санофи Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
EP3701046A1 (en) * 2017-10-27 2020-09-02 SVAR Life Science AB Secreted reporter-peptides for optimizing cell-based assays for analysis on immuno-assay platforms
CN116098989A (zh) * 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
CN114903978A (zh) 2018-07-03 2022-08-16 百时美施贵宝公司 Fgf-21配制品
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
GB2625224A (en) * 2021-09-08 2024-06-12 Leto Laboratories Co Ltd FGF21 mutant protein and use thereof
WO2023046071A1 (zh) 2021-09-23 2023-03-30 江苏恒瑞医药股份有限公司 抗klb抗体及用途
WO2023064808A1 (en) 2021-10-13 2023-04-20 Akero Therapeutics, Inc. Pharmaceutical compositions of efruxifermin
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
JP3039802B2 (ja) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
EP0779362B2 (en) 1989-12-22 2012-06-13 Laboratoires Serono SA DNA constructs for endogenous gene activation and expression modification
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
EP1403285A1 (en) 1990-07-06 2004-03-31 Gencell S.A. Fibroblast growth factor receptors
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
CA2136439A1 (en) 1992-06-18 1994-01-06 Michael Philip Nova Process for detection of neoplastic disease
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
GB9313210D0 (en) * 1993-06-25 1993-08-11 Sandoz Ltd Novel combinations
JPH08509870A (ja) 1993-05-26 1996-10-22 オンタリオ キャンサー インスティテュート 特定のｃｄ４５イソ型タンパク質の発現を遮断するトランスジェニック哺乳動物
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
DE705334T1 (de) 1993-06-14 1999-12-30 Basf Ag Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5469743A (en) * 1993-06-24 1995-11-28 Zorn; Roger H. Dynamic surface wave roll inspection device
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5654166A (en) * 1994-11-09 1997-08-05 Kurth; Gerhard P. Process of preparing hormone-free bovine cartilage for dosage form
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
JPH11506319A (ja) 1995-05-26 1999-06-08 ゼネカ・リミテッド エクジソンレセプターを含む遺伝子スイッチ
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
ATE465149T1 (de) 1996-02-28 2010-05-15 Ariad Pharma Inc Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
CN1167795C (zh) 1996-12-26 2004-09-22 协和发酵工业株式会社 肽、dna及抗体
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6150096A (en) * 1997-09-26 2000-11-21 Universite De Sherbrooke Molecular markers for the diagnosis of human diseases including Crohn's disease
DE69839571D1 (de) 1997-11-25 2008-07-10 Genentech Inc Fibroblasten-wachstumsfaktor-19
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000027885A1 (fr) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
JP2002539176A (ja) 1999-03-15 2002-11-19 カイロン コーポレイション 眼の疾患を処置または予防するための組換え遺伝子送達ベクターの使用
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US7108984B2 (en) 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20040018499A1 (en) 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
MXPA04000231A (es) 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
US20050187150A1 (en) 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
AU2003201810A1 (en) 2002-01-15 2003-07-30 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP1332761A1 (en) 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
CN100531796C (zh) 2002-01-31 2009-08-26 马普科技促进协会 Fgfr激动剂
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (ja) 2002-05-22 2003-11-25 Pharma Design Inc ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
TWI300430B (en) * 2003-01-10 2008-09-01 Ritek Corp Optical recording medium dye and optical recording medium using thereof
EP1586090B1 (en) * 2003-01-23 2012-03-21 LG Electronics, Inc. Recording medium with copy protection information formed in intermittent or alternate wobbled pits and apparatus and methods for forming, recording, and reproducing the recording medium
WO2004083381A2 (en) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
SI1641483T1 (sl) 2003-06-12 2008-08-31 Lilly Co Eli Fuzijski proteini
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PT1680140E (pt) 2003-10-16 2011-05-31 Imclone Llc Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
JP4477013B2 (ja) 2003-12-10 2010-06-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2005072769A1 (en) 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
US7887790B2 (en) * 2004-02-20 2011-02-15 Cornell Research Foundation, Inc. Polymers and polymer coatings
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP4505631B2 (ja) 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
PT1789442E (pt) * 2004-09-02 2009-11-11 Lilly Co Eli Muteínas do factor de crescimento de fibroblasto 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JP2006246823A (ja) 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用
WO2006130527A2 (en) 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
US7395962B2 (en) 2005-10-28 2008-07-08 United Parcel Service Of America, Inc. Pick up notice and method of using same
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
WO2007056789A1 (en) 2005-11-16 2007-05-24 Dier Corporation As Trustee For The Reid Family Superannuation Trust New frame assemblies for security screens
EP1996216A2 (en) 2006-02-28 2008-12-03 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
WO2008066498A1 (en) 2006-12-01 2008-06-05 Agency For Science, Technology And Research Cancer-related protein kinases
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2682096A1 (en) 2007-04-02 2009-01-15 Genentech, Inc. Klotho beta
JP5187837B2 (ja) 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
WO2008135993A1 (en) 2007-05-08 2008-11-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
KR20100017169A (ko) 2007-05-22 2010-02-16 노파르티스 아게 Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
WO2008149521A1 (ja) 2007-05-29 2008-12-11 Immuno-Biological Labolatories Co., Ltd 癌治療剤及び癌の治療方法
JP2010531135A (ja) 2007-06-04 2010-09-24 ノボ ノルディスク アクティーゼルスカブ Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
EP2185178B1 (en) 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
GB2464062A (en) 2007-08-08 2010-04-07 Foster Miller Inc Watercraft drogue system
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
DK3248610T3 (da) * 2009-05-05 2024-01-15 Amgen Inc Fgf21-mutanter og anvendelser deraf

Also Published As

Publication number Publication date
US20100285131A1 (en) 2010-11-11
CA2760196A1 (en) 2010-11-11
EP3248610B1 (en) 2023-12-20
US8795985B2 (en) 2014-08-05
TWI436776B (zh) 2014-05-11
JO3469B1 (ar) 2020-07-05
PT3248610T (pt) 2024-02-01
UY38740A (es) 2020-12-31
PH12015502433B1 (en) 2017-01-16
US20120178685A1 (en) 2012-07-12
TW201446793A (zh) 2014-12-16
CN107188950A (zh) 2017-09-22
TW201105345A (en) 2011-02-16
MY156542A (en) 2016-02-26
FI3248610T3 (fi) 2024-01-18
BRPI1011404B1 (pt) 2022-05-03
SG10201707763PA (en) 2017-11-29
WO2010129503A1 (en) 2010-11-11
LT3248610T (lt) 2024-01-25
CR20110639A (es) 2012-01-06
EP2427208A1 (en) 2012-03-14
CN102655877B (zh) 2017-04-05
PL3248610T3 (pl) 2024-04-02
CN107188950B (zh) 2021-09-28
AR076541A1 (es) 2011-06-22
IL215937A0 (en) 2011-12-29
EP4353247A2 (en) 2024-04-17
KR20180014235A (ko) 2018-02-07
AU2010246108A1 (en) 2011-11-24
HUE065036T2 (hu) 2024-04-28
PE20160718A1 (es) 2016-08-03
EP3248610A1 (en) 2017-11-29
ES2632742T3 (es) 2017-09-15
SI3248610T1 (sl) 2024-03-29
IL242377A (en) 2016-12-29
US8188040B2 (en) 2012-05-29
TWI560197B (en) 2016-12-01
IL215937A (en) 2015-11-30
CL2011002768A1 (es) 2012-08-24
HK1247134A1 (zh) 2018-09-21
KR101860572B1 (ko) 2018-05-24
SG175861A1 (en) 2011-12-29
EP2427208B1 (en) 2017-04-26
EA201171220A1 (ru) 2012-05-30
MA33716B1 (fr) 2012-11-01
ZA201108371B (en) 2012-07-25
US8618053B2 (en) 2013-12-31
US8835385B2 (en) 2014-09-16
AU2010246108B2 (en) 2014-10-23
DK3248610T3 (da) 2024-01-15
CA2760196C (en) 2019-02-26
CN102655877A (zh) 2012-09-05
KR20120068764A (ko) 2012-06-27
JP5823954B2 (ja) 2015-11-25
ES2969528T3 (es) 2024-05-21
PE20120358A1 (es) 2012-04-26
RS65153B1 (sr) 2024-02-29
SG10201402038WA (en) 2014-07-30
US20120213779A1 (en) 2012-08-23
JP2012525844A (ja) 2012-10-25
US20120177646A1 (en) 2012-07-12
EA021425B1 (ru) 2015-06-30
UY32607A (es) 2010-12-31
PH12015502433A1 (en) 2017-01-16
MX2011011709A (es) 2012-02-29
HRP20240135T1 (hr) 2024-04-12
BRPI1011404A2 (pt) 2016-03-15
NZ596037A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
CO6470863A2 (es) Mutantes fgf21 y usos de los mismos
EA201270758A1 (ru) Мутанты fgf21 и их применение
EA201990619A1 (ru) Fgf21 мутанты и их применение
MX2009002816A (es) Proteinas de fusion de albumina.
TNSN08064A1 (en) Albumin fusion proteins
EA201891127A1 (ru) Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
IN2012DN02981A (es)
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
WO2007146038A3 (en) Albumin fusion proteins
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
MX2010005816A (es) Epítopos de péptido de stat3.
GB201018125D0 (en) Peptide
WO2018074498A8 (ja) リムルス属由来の組換え蛋白質及びこれをコードするｄｎａ
MX2021008126A (es) Vacuna de arnm.
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
TN2011000553A1 (en) Fgf21 mutants and uses thereof
UA102395C2 (en) Fgf21 mutants and use thereof
BR112012024138B8 (pt) peptídeo anticoncepcional derivado do veneno da aranha latrodectus mirabilis, sequência nucleotídica, métodos para a obtenção do peptídeo, composição farmacêutica e usos do peptídeo e da composição farmacêutica

Legal Events

Date Code Title Description
FC Application refused